Skip to contentA
Autolus Therapeutics plc
A
AUTLAutolus Therapeutics plc Q2 2026 · 10-Q
Revenue$45.69M$45.69M+118.4% vs Q2 2025 Net Income-$39.11M-$39.11MN/M vs Q2 2025 EPS Diluted-$0.15-$0.15N/M vs Q2 2025 Operating Income-$43,838,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Autolus Therapeutics plc · CIK 1730463 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$25,982,000N/M Margins · derivedOperating margin-95.9%+196.6 pt vs Q2 2025
Net margin-85.6%+143.4 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 11, 2026 · 42 d after period end